Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 August 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Rapid infliximab infusions are safe

A study published ahead of print in the Alimentary Pharmacology & Therapeutics investigates the risk of infusion reactions associated with infliximab therapy for inflammatory conditions.

News image

Infliximab is typically administered intravenously via 2- to 3-hour duration infusions.

Infusions are time-consuming and costly.

Shorter duration infusions are administered at some centers.

Limited safety data are available on shorter duration infusions.

Dr Adler and colleagues from Michigan, USA determined the risk of infusion reaction associated with standard 2- to 3-hour infusions vs. rapid infusions in patients receiving infliximab therapy for inflammatory bowel disease (IBD), rheumatoid arthritis, spondylarthopathy and psoriatic disease.

MEDLINE, Embase, and Web of Science were searched.

Inclusion required human subjects, documentation of number of standard and rapid infliximab infusions and number of incident infusion reactions.

7 studies limited to IBD demonstrated decreased risk of reaction
Alimentary Pharmacology & Therapeutics

Studies of overlapping populations were excluded.

The team reported that 3 reviewers independently extracted data, and study quality was assessed.

The research team identified 10 studies comprising 13 147 standard 2- to 3-hours, and 8497 at 1-hour or less of infliximab infusions.

The team identified 9 studies that reported the risk of infusion reaction in standard vs. 1-hour infusions, demonstrating decreased relative risk of infusion reaction with 1-hour vs. standard infusions.

The researchers found that 7 studies limited to IBD also demonstrated decreased risk of reaction.

Other comparisons demonstrated no difference in relative risk of reaction, including concomitant medication use or analysis limited to high and medium quality studies.

Dr Adler's team commented, "Rapid infliximab infusions of 1-hour or less duration are not associated with increased risk of infusion reaction when compared to standard 2- to 3-hours infusions in selected patients who previously tolerated 3 to 4 standard infusions."

"One-hour infusions will conserve health care resources and may lead to improved adherence and quality of life in patients receiving infliximab."

Aliment Pharmacol Ther 2013: 38(3): DOI: 10.1111/apt.12389
03 July 2013

Go to top of page Email this page Email this page to a colleague

 24 August 2016 
Genetics and therapy response in IBD
 24 August 2016 
Obeticholic acid for primary biliary cholangitis
 24 August 2016 
Hep B after infant vaccination program
 23 August 2016 
Colorectal cancer genetics as biomarkers
 23 August 2016 
Prognostic test for mortality after liver transplant
 23 August 2016 
Postoperative mortality in elderly with IBD
 22 August 2016 
Celiac disease in the elderly
 22 August 2016 
Laparoscopic vs open colectomy databases
 22 August 2016 
Mucosal healing and ulcerative colitis outcomes
 19 August 2016 
Dietary questionnaire for GI clinics
 19 August 2016 
Botox treatment for chronic anal fissure
 19 August 2016 
Myeloid-derived suppressor cells in GI cancers
 18 August 2016 
Gallstone formation determinants
 18 August 2016 
Age disparities in IBD therapy
 18 August 2016 
Seasonal variation in diverticulitis
 17 August 2016 
IBD activity score for routine clinical use
 17 August 2016 
Attitudes to H. pylori in primary care
 17 August 2016 
Nonselective β-blockers and mortality in cirrhosis
 16 August 2016 
Upper GI lesions in adults with IBD
 16 August 2016 
C. difficile infection and mortality when managed by GI surgeons
 16 August 2016 
HCV eradication in cirrhosis
 15 August 2016 
Predicting favorable outcomes in IBD
 15 August 2016 
Scoring system predicted microscopic colitis
 15 August 2016 
Mortality in spontaneous bacterial peritonitis
 12 August 2016 
Recurrence of resected gastric cancer
 12 August 2016 
Screening for pancreatic cancer
 12 August 2016 
Index for diagnostic accuracy of Crohn's
 11 August 2016 
Bowel disease in primary care patients with bowel symptoms
 11 August 2016 
Diagnosis in covert hepatic encephalopathy
 11 August 2016 
Colorectal neoplasm on surveillance colonoscopies
 10 August 2016 
Maintenance therapy for children with eosinophilic esophagitis
 10 August 2016 
Moderate alcohol use and insulin action in HCV
 10 August 2016 
Consensus on the management of GERD
 09 August 2016 
Pancreatitis quality of life instrument
 09 August 2016 
Gallstone disease and NAFLD
 09 August 2016 
Steroid dependency and IBD
 08 August 2016 
Venous thromboembolism in celiac disease
 08 August 2016 
C. diff in IBD 
 08 August 2016 
Gut-directed hypnotherapy vs low FODMAP diet in IBS
 05 August 2016 
Therapy for H.pylori treatment
 05 August 2016 
Obesity and the development of NAFLD
 05 August 2016 
Obesity and CVD in celiac disease
 04 August 2016 
Novel risk factor for post-ERCP pancreatitis
 04 August 2016 
Bleeding after endoscopic resection of colorectal lesions
 04 August 2016 
Ondansetron for children with acute gastroenteritis
 03 August 2016 
Post-colonoscopy complications
 03 August 2016 
IVF in women with IBD
 03 August 2016 
Post-operative pancreatic fistulae after pancreatic surgery
 02 August 2016 
H. pylori in children
 02 August 2016 
Gastric cancer in patients with gastric intestinal metaplasia
 02 August 2016 
Behavioral changes and bariatric surgery
 01 August 2016 
Relapse after cessation of oral antiviral treatment in Hep B
 01 August 2016 
Antimicrobial resistance of H. pylori
 01 August 2016 
Colorectal cancers in IBD
 29 July 2016 
Susceptibility loci for gallstone disease
 29 July 2016 
Tool to diagnose Helicobacter-negative gastritis
 29 July 2016 
H. pylori clarithromycin resistance in the USA
 28 July 2016 
HCV eradication in cirrhotic patients
 28 July 2016 
Hep B screening and immunosuppressive therapy
 28 July 2016 
Pancreatitis after ERCP

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us